Identification of the Major Steps in Botulinum Toxin Action

Annual Review of Pharmacology and Toxicology

Volumn 44, Issue , 2004, Pages 167-193

  Simpson, Lance L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Acetylcholine; Airway epithelia; Endoprotease; Gut epithelia; Neuromuscular junction

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN; PROTEINASE; VACCINE;

ACETYLCHOLINE RELEASE; CHOLINERGIC NERVE; CHOLINERGIC TRANSMISSION; CLOSTRIDIUM BARATII; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM BUTYRICUM; DRUG ABSORPTION; DRUG MECHANISM; ENDOCYTOSIS; HUMAN; INTESTINE EPITHELIUM; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RESPIRATORY EPITHELIUM; REVIEW; TRANSPORT KINETICS; VASCULARIZATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; BOTULINUM TOXINS; CHOLINERGIC FIBERS; DIGESTIVE SYSTEM; HUMANS; MEMBRANE TRANSPORT PROTEINS; NEUROMUSCULAR JUNCTION; VACCINES;

CLOSTRIDIUM BARATII; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM BUTYRICUM;

EID: 1342323663     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.44.101802.121554     Document Type: Review

References (132)

1. Lamanna C. 1959. The most poisonous poison. Science 130:763-72
2. Hatheway CL. 1995. Botulism: the present status of the disease. Curr. Top. Microbiol. Immunol. 195:55-75
3. Shapiro RL, Hatheway C, Swerdlow DL. 1998. Botulism in the United States: a clinical and epidemiologic review. Ann. Intern. Med. 129:221-28
4. Franz DR, Jahrling PB, Friedlander AM, McClaine DJ, Hoover DL, et al. 1997. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278:399-411
5. Amon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, et al. 2001. Botulinum toxin as a biological weapon. JAMA 285:1059-70
6. Atlas RM. 2002. Bioterrorism: from threat to reality. Annu. Rev. Microbiol. 56:167-85
7. Jankovic J, Brin MF. 1991. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 324:1186-94
8. Jankovic J, Hallett M, eds. 1994. Therapy with Botulinum Toxin. New York: Marcel Dekker. 608 pp.
9. Schantz EJ, Johnson EA. 1997. Botulinum toxin: the story of its development for the treatment of human disease. Perspect. Biol. Med. 40:317-27
10. Bell MS, Vermeulen LC, Sperling KB. 2000. Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin. Rev. Ther. 20:1079-91
11. Simpson LL, Maksymowych AB, Kiyatkin N. 1999. Botulinum toxin as a carrier for oral vaccines. Cell. Mol. Life Sci. 56:47-61
12. Maksymowych AB, Simpson LL. 1998. Binding and transcytosis of botulinum toxin by polarized human colon carcinoma, cells. J. Biol. Chem. 273:21950-57
13. Park JB, Simpson LL. 2003. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect. Immun. 71:1147-54
14. Simpson LL. 1980. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J. Pharmacol. Exp. Ther. 213: 504-8
15. Simpson LL. 1981. The origin, structure and pharmacological activity of botulinum toxin. Pharmacol. Rev. 33:155-88
16. Herreros J, Lalli G, Montecucco C, Schiavo G. 1999. Pathophysiological properties of clostridial neurotoxins. See Ref. 132, pp. 202-28
17. Humeau Y, Doussau F, Grant NJ, Poulain B. 2000. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82:427-46
18. Schiavo G, Matteoli M, Montecucco C. 2000. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80:717-66
19. Simpson LL. 2000. Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs. Biochimie 82:943-53
20. Gimenez DF, Gimenez JA. 1993. Serological subtypes of botulinal neurotoxins. In Botulinum and Tetanus Neurotoxins, ed. BR DasGupta, pp. 421-31. New York: Plenum
21. Sakaguchi G. 1983. Clostridium botulinum toxins. Pharmacol. Ther. 19:165-94
22. Minton NP. 1995. Molecular genetics of clostridial neurotoxins. Curr. Top. Microbiol. Immunol. 195:161-94
23. Oguma K, Fujinaga Y, Inoue K. 1995. Structure and function of Clostridium botulinum toxins. Microbiol. Immunol. 39: 161-68
24. Lacy BD, Stevens RC. 1999. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291: 1091-104
25. Popoff MR, Marvaud J-C. 1999. Structural and genomic features of clostridial neurotoxins. See Ref. 132, pp. 174-201
26. Hatheway CL. 1988. Botulism: the present status of the disease. In Clostridial Neurotoxins, ed. C Montecucco, pp. 55-75. Berlin: Springer-Verlag
27. Habermann E, Dreyer F. 1986. Clostridial neurotoxins: handling and action at the cellular and molecular level. Curr. Top. Microbiol. Immunol. 129:94-179
28. Ahnert-Hilger G, Bigalke H. 1995. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog. Neurobiol. 46:83-96
29. Raciborska DA, Charlton MP. 1999. Retention of cleaved synaptosome-associated protein of 25 kDa (SNAP-25) in neuromuscular junctions: a new hypothesis to explain persistence of botulinum A poisoning. Can. J. Pharmacol. 77:679-88
30. Keller JE, Neale EA. 2001. The role of the synaptic protein SNAP-25 in the potency of botulinum neurotoxin type A. J. Biol. Chem. 276:13476-82
31. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, et al. 2003. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, Cl, E, and F compared with the long lasting type A. J. Biol. Chem. 278:1363-71
32. Amon SS. 1980. Infant botulism. Annu. Rev. Med. 31:541-60
33. Wilcke BW, Midura TF, Amon SS. 1980. Quantitative evidence of intestinal colonization by Clostridium botulinum in four cases of infant botulism. J. Infect. Dis. 141:419-23
34. Wigginton JM, Thill P. 1993. Infant botulism. Clin. Pediatr. 32:669-74
35. Midura TF. 1996. Update: infant botulism. Clin. Microbiol. Rev. 9:119-25
36. Chia JK, Clark JB, Ryan CA, Pollack M. 1986. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N. Engl. J. Med. 315:239-41
37. Fujinaga Y, Inoue K, Watanabe S, Yokota K, Hirai Y, et al. 1997. The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin. Microbiology 143:3841-47
38. Fujinaga Y, Inoue K, Nomura T, Sasaki J, Marvaud JC, et al. 2000. Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythocytes. FEBS Lett. 467: 179-83
39. Inoue K, Fujinaga Y, Honke K, Arimitsu H, Mahmut N, et al. 2001. Clostridium botulinum type A haemagglutinin-positive progenitor toxin (HA+-PTX) binds to oligosaccharides containing Galβ1-4GlcNAc through one subcomponent of haemagglutinin (HA1). Microbiology 147:811-19
40. Maksymowych AB, Reinhard M, Malizio CJ, Goodnough MC, Johnson EA, et al. 1999. Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect. Immun. 67:4708-12
41. Maksymowych AB, Simpson LL. 2003. Structural features of botulinum. neurotoxin that govern binding and transcytosis across polarized human intestinal epithelial cells. Submitted
42. Ahsan CR, Hajnoczky G, Muktar M, Maksymowych AB, Simpson LL. 2003. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. Submitted
43. Maksymowych AB, Park J-B, Simpson LL. 2003. An assessment of the role of M cells and the Peyer's Patch complex in the absorption of botulinum toxin and in the induction of a systemic immune response. Submitted
44. Kerneis S, Bogdanova A, Kraehenbuhl J-P, Pringault E. 1997. Conversion by Peyer's Patch lymphocytes of human enterocytes into M Cells that transport bacteria. Science 277:949-52
45. Middlebrook JL, Brown JE. 1995. Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Curr. Top. Microbiol. Immunol. 195:89-122
46. Atassi MZ, Oshima M. 1999. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit. Rev. Immunol. 19:219-60
47. Byrne MP, Smith LA. 2000. Development of vaccines for prevention of botulism. Biochimie 82:955-66
48. Kiyatkin N, Maksymowych AB, Simpson LL. 1997. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect. Immun. 65:4586-91
49. Holzer VE. 1962. Botulisimus durch inhalation. Med. Klin. 57:1735-38
50. Halliwell G. 1954. The action of proteolytic enzymes on Clostridium botulinum type A toxin. Biochem. J. 58:4-8
51. Ohishi I. 1984. Oral toxicities of Clostridium botulinum type A and B toxins from different strains. Infect. Immun. 43:487-90
52. Ohishi I, Sakaguchi G. 1980. Oral toxicities of Clostridium botulinum type C and D toxins of different molecular size. Infect. Immun. 28:303-9
53. Ohishi I, Sugii S, Sakaguchi G. 1977. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect. Immun. 16:107-9
54. Sugii S, Ohishi I, Sakaguchi G. 1977. Intestinal absorption of botulinum toxins of different molecular sizes in rats. Infect. Immun. 17:491-96
55. Chen F, Kuziemko GM, Stevens RC. 1998. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect. Immun. 66:2420-25
56. Burgen ASV, Dickens F, Zatman LJ. 1949. The action of botulinum toxin on the neuromuscular junction. J. Physiol. 109:10-24
57. 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiograpic localization and quatitation of distinct membrane acceptors for types A and B on motor nerves. J. Cell Biol. 103: 521-34
58. 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J. Cell Biol. 103:535-44
59. Simpson LL, Rapport MM. 1971. Ganglioside inactivation of botulinum toxin. J. Neurochem. 18:1341-43
60. Simpson LL, Rapport MM. 1971. The binding of botulinum toxin to membrane lipids: sphingolipids, steroids, and fatty acids. J. Neurochem. 18:1751-59
61. Kitamura M, Iwamori M, Nagai Y. 1980. Interaction between Clostridium botulinum neurotoxin and gangliosides. Biochim. Biophys. Acta 628:328-35
62. T1b on the activities of Clostridium botulinum toxins. FEMS Microbiol. Lett. 21:219-23
63. 1b ganglioside in Clostridium botulinum type C neurotoxin. J. Biochem. 97:213-18
64. Ochanda JO, Syuto B, Ohishi I, Naiki M, Kubo S. 1986. Binding of Clostridium botulinum neurotoxin to gangliosides. J. Biochem. 100:27-33
65. Schengrund C-L, DasGupta BR, Ringler NJ. 1991. Binding of botulinum and tetanus neurotoxins to gangliosides GT1b and derivatives thereof. J. Neurochem. 57:1024-32
66. Kamata Y, Kimura Y, Hiroi T, Sakaguchi G, Kozaki S. 1993. Purification and characterization of the ganglioside-binding fragment of Clostridium botulinum type E neurotoxin. Biochim. Biophys. Acta 1156:213-18
67. Kamata Y, Yoshimoto M, Kozaki S. 1997. Interaction between botulinum neurotoxin type A and ganglioside: ganglioside inactivates the neurotoxin and quenches its tryptophan fluorescence. Toxicon 35:1337-40
68. Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S. 1998. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb. Pathog. 25:91-99
69. Bakry N, Kamata Y, Simpson LL. 1991. Lectins from triticum vulgaris and limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin . J. Pharmacol. Exp. Ther. 258:830-36
70. Kitamura M, Takamiya K, Aizawa S, Furukawa K, Furukawa K. 1999. Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice. Biochim. Biophys. Acta 1441:1-3
71. Bullens RWM, O'Hanlon GM, Wagner E, Molenaar PC, Furukawa K, et al. 2002. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J. Neurosci. 22:6876-84
72. Yowler BC, Kensinger RD, Schengrund C-L. 2002. Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem. 227:32815-19
73. Montecucco C. 1986. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem. Sci. 11:315-17
74. Middlebrook JL. 1989. Cell surface receptors for protein toxins. In Botulinum Neurotoxin and Tetanus Toxin, ed. LL Simpson, pp. 95-119. San Diego: Academic
75. Daniels-Holgate PU, Dolly JO. 1996. Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain. J. Neurosci. Res. 44:263-71
76. Lalli G, Herreros J, Osborne SL, Montecucco C, Rossetto O, et al. 1999. Functional characterization of tetanus and botulinum neurotoxins binding domains. J. Cell Sci. 112:2715-24
77. Nishiki T, Ogasawara J, Kamata Y, Kozaki S. 1993. Solubilization and characterization of the acceptor for Clostridum botulinum type B neurotoxin from rat brain synaptic membranes. Biochim. Biophys. Acta 1158:333-38
78. Nishiki T, Kamata Y, Nemoto Y, Omori A, Ito T, et al. 1994. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 269:10498-503
79. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, et al. 1996. Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA. Neurosci. Lett. 208:105-8
80. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, et al. 996. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 378:253-57
81. Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S. 1998. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins Microb. Pathog. 25:91-99
82. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. 1998. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5:898-902
83. Swaminathan S, Eswaramoorthy S. 2000. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7:693-99
84. Kamata Y, Kozaki S, Sakaguchi G. 1988. Effects of pH on the binding of Clostridium botulinum type E derivative toxin to gangliosides and phospholipids. FEMS Microbiol. Lett. 55:71-76
85. c of tetanus neurotoxin. Nat. Struct. Biol. 4:788-92
86. Ginalski K, Venclovas C, Lesyng B, Fidelis K. 2000. Structure-based sequence alignment for the β-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. FEBS Lett. 482:119-24
87. Sutton JM, Chow-Worn O, Spaven L, Silman NJ, Hallis B, et al. 2001. Tyrosine-1290 of tetanus neurotoxin plays a key role in its binding to gangliosides and functional binding to neurons. FEBS Lett. 493:45-49
88. Fotinou C, Emsley P, Black I, Andos H, Ishida H, et al. 2001. The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J. Biol. Chem. 276:32274-81
89. cc-domain of tetanus neurotoxin are required for toxicity. J. Mol. Biol. 326:835-47
90. Matthews G. 1996. Neurotransmitter release. Annu. Rev. Neurosci. 19:219-33
91. Betz WJ, Angleson JK. 1998. The synaptic vesicle cycle. Annu. Rev. Physiol. 60:347-63
92. Matteoli M, Takei K, Perin MS, Sudhof TC, De Camilli P. 1992. Exo-endocytotic recycling of synaptic vesicles in developing processes of cultured hippocampal neurons. J. Cell Biol. 177:849-61
93. Sandvig K. 2003. Transport of toxins across intracellular membranes. In Bacterial Protein Toxins, ed. DL Burns, JT Barbier, BH Iglewski, pp. 157-72. Washington, DC: ASM
94. Simpson LL. 1982. The interaction between aminoquinolines and presynaptically acting neurotoxins. J. Pharmacol. Exp. Ther. 222:43-48
95. Simpson LL. 1983. Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. J. Pharmacol. Exp. Ther. 225:546-52
96. Simpson LL, Coffield JA, Bakry N. 1994. Inhibition of vacuolar adenosine triphosphatase anatagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J. Pharmacol. Exp. Ther. 269:256-62
97. Hoch DH, Romero-Mira M, Ehrlich BE, Finkelstein A, DasGupta BR, et al. 1985. Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes. Proc. Natl. Acad. Sci. USA 82:1692-96
98. Koriazova LK, Montal M. 2003. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 10:13-18
99. Simpson LL, Maksymowych AB, Hao S. 2001. The role of zinc binding in the biological activity of botulinum toxin. J. Biol. Chem. 276:27034-41
100. Gundersen CB. 1980. The effects of botulinum toxin on the synthesis, storage and release of acetylcholine. Prog. Neurobiol. 14:99-119
101. Howard BD, Gundersen CB Jr. 1980. Effects and mechanisms of polypeptide neurotoxins that act presynaptically. Annu. Rev. Pharmacol. Toxicol. 20:307-36
102. Gundersen CB, Katz B, Miledi R. 1981. The reduction of endplate responses by botulinum toxin. Proc. R. Soc. London Ser. B 213:489-93
103. Kim YI, Lomo T, Lupa MT, Thesleff S. 1984. Miniature end-plate potentials in rat skeletal muscle poisoned with botulinum toxin. J. Physiol. 356:587-99
104. Dolly JO, Lande S, Wray DW. 1987. The effects of in vitro applications of purified botulinum neurotoxin at mouse motor nerve terminals. J. Physiol. 386:475-84
105. Harris AJ, Miledi R. 1971. The effect of type D botulinum toxin on frog neuromuscular junctions. J. Physiol. 217:497-515
106. Dreyer F, Schmitt A. 1983. Transmitter release in tetanus and botulinum A toxin-poisoned mammalian motor endplates and its dependence on nerve stimulation and temperature. Pflugers Arch. 399: 228-34
107. Sellin LC, Thesleff S, DasGupta BR. 1983. Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction. Acta Physiol. Scand. 119:127-33
108. Gansel M, Penner R, Dreyer F. 1987. Distinct sites of action of clostridium neurotoxins revealed by double-poisoning of mouse motor nerve terminals. Pflugers Arch. 409:533-39
109. Molgo J, DasGupta BR, Thesleff S. 1989. Characterization of the actions of botulinum neurotoxin type E at the rat neuromuscular junction. Acta Physiol. Scand. 137:497-501
110. Molgo J, Siegel LS, Tabti N, Thesleff S. 1989. A study of synchronization of quantal transmitter release from mammalian motor endings by the use of botulinum toxins type A and D. J. Physiol. 411:195-205
111. Kao I, Drachman DB, Price DL. 1976. Botulinum toxin: mechanism of presyanptic blockade. Science 193:1256-58
112. Dreyer F, Rosenberg F, Becker C, Bigalke H, Penner R. 1987. Differential effects of various secretagogues on equantal transmitter release from mouse motor nerve terminals treated with botulinum A and tetanus toxin. Naunyn-Schmiedebergs Arch. Pharmacol. 335:1-7
113. Binz T, Kurazono H, Wille M, Frevert J, Wernars K, et al. 1990. The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J. Biol. Chem. 265:9153-58
114. Thompson DE, Brehm JK, Oultram JD, Swinfield T-J, Shone CC, et al. 1990. The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. Eur. J. Biochem. 189:73-81
115. Whelan SM, Elmore MJ, Bodsworth NJ, Brehm JK, Atkinson T, et al. 1992. Molecular cloning of the Clostridum botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl. Environ. Microbiol. 58:2345-54
116. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, et al. 1992. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359:832-35
117. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, et al. 1993. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365:160-63
118. Blasi J, Chapman ER, Yamasaki S, Binz T, Niemann H, et al. 1993. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J. 12:4821-28
119. Schiavo G, Rossetto O, Catsicas S, Polverino de Laureto P, DasGupta BR, et al. 1993. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J. Biol. Chem. 268: 23784-87
120. Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, et al. 1993. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J. Biol. Chem. 269:1617-20
121. Schiavo G, Malizio C, Trimble WS, Polverino de Laureto P, Milan G, et al. 1994. Botulinum G neurotoxin cleaves at a single Ala-Ala peptide bond. J. Biol. Chem. 269:20213-16
122. Yamasaki S, Baumeister A, Binz T, Blasi J, Link E, et al. 1994. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem. 269: 12764-72
123. 82 bond of rat synaptobrevin 2. Biochem. Biophys. Res. Commun. 200:829-35
124. Foran P, Lawrence GW, Shone CC, Foster KA, Dolly JO. 1996. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry 35:2630-36
125. Williamson LC, Halpern JL, Montecucco C, Brown JE, Neale EA. 1996. Clostridial neurotoxins and substrate proteolysis in intact neurons. J. Biol. Chem. 271:7694-99
126. Rossetto O, Schiavo G, Montecucco C, Poulain B, Deloye F, et al. 1994. SNARE motif and neurotoxins. Nature 372:415-16
127. Eleopra R, Tungnoli V, Rossetto O, De Grandis D, Montecucco C. 1998. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci. Lett. 256:135-38
128. Keller JE, Neale EA, Oyler G, Adler M. 1999. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 456:137-42
129. Adler M, Keller JE, Sheridan RE, Deshpande SS. 2001. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 39:233-43
130. Meunier FA, Lisk G, Sesardic D, Dolly JO. 2003. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol. Cell. Neurosci. 22:1-13
131. Kuranzono H, Mochida S, Binz T, Eisel U, Quanz M, et al. 1992. Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin type A. J. Biol. Chem. 267:14721-29
132. Alouf JE, Freer JH, eds. 1999. Comprehensive Sourcebook of Bacterial Protein Toxins. London: Academic